Literature DB >> 15181052

The prevalence and features of the polycystic ovary syndrome in an unselected population.

Ricardo Azziz1, Keslie S Woods, Rosario Reyna, Timothy J Key, Eric S Knochenhauer, Bulent O Yildiz.   

Abstract

Notwithstanding the potential public health impact of the polycystic ovary syndrome (PCOS), estimates regarding its prevalence are limited and unclear. Between July 1998 and October 1999, 400 unselected consecutive premenopausal women (18-45 yr of age) seeking a preemployment physical at the University of Alabama at Birmingham were studied (223 Black, 166 White, and 11 of other races). Evaluation included a history and physical examination, a modified Ferriman-Gallwey hirsutism score, and serum screening for hyperandrogenemia, hyperprolactinemia, and 21-hydroxylase-deficient nonclassical adrenal hyperplasia. PCOS was diagnosed by the presence of the following: 1) oligoovulation, 2) hyperandrogenemia and/or hirsutism (modified Ferriman-Gallwey score > or = 6), and 3) the exclusion of related disorders. Confirmed PCOS was established in those individuals whose evaluation was complete and indicative of PCOS, and possible PCOS was established when the hormonal evaluation was not complete or was unavailable, but the clinical phenotype was otherwise suggestive of the disorder. The individual probability of PCOS in women with possible PCOS was assigned a weight based on the findings in similar subjects whose evaluation was complete, and the total number of PCOS cases arising from these individuals was calculated (i.e. individual probability of PCOS x total number of subjects in the group). The cumulative prevalence of PCOS in our population was 6.6% (26.5 of 400), including 15 subjects among the 347 women completing their evaluation and a calculated prevalence of 11.5 subjects among the remainder. The prevalence rates of PCOS for Black and White women were 8.0 and 4.8%, respectively, not significantly different. These data from a large representative unselected population support the concept that PCOS is the most common endocrine abnormality of reproductive-aged women in the United States.

Entities:  

Mesh:

Year:  2004        PMID: 15181052     DOI: 10.1210/jc.2003-032046

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  632 in total

Review 1.  PCOS in adolescence and type 2 diabetes.

Authors:  Anne-Marie Carreau; Jean-Patrice Baillargeon
Journal:  Curr Diab Rep       Date:  2015-01       Impact factor: 4.810

2.  Histological evaluation of rat larynx in experimental polycystic ovary syndrome model.

Authors:  Hande Senem Deveci; Ildem Deveci; Mehmet Habesoglu; Mehmet Sürmeli; Vefa Kınıs; Murat Eriman; Pembegul Gunes; Murat Yekrek; Erol Egeli
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-03-11       Impact factor: 2.503

3.  Evidence for metabolic and reproductive phenotypes in mothers of women with polycystic ovary syndrome.

Authors:  Susan Sam; Richard S Legro; Paulina A Essah; Teimuraz Apridonidze; Andrea Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-21       Impact factor: 11.205

4.  Metformin during pregnancy in polycystic ovary syndrome: another vitamin bites the dust.

Authors:  Richard S Legro
Journal:  J Clin Endocrinol Metab       Date:  2010-12       Impact factor: 5.958

5.  Steroidogenic regulatory factor FOS is underexpressed in polycystic ovary syndrome (PCOS) adipose tissue and genetically associated with PCOS susceptibility.

Authors:  Michelle R Jones; Gregorio Chazenbalk; Ning Xu; Angela K Chua; Tamar Eigler; Emebet Mengesha; Yen-Hao Chen; Jung-Min Lee; Marita Pall; Xiaohui Li; Yii-Der I Chen; Kent D Taylor; Ruchi Mathur; Ronald M Krauss; Jerome I Rotter; Richard S Legro; Ricardo Azziz; Mark O Goodarzi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-21       Impact factor: 5.958

Review 6.  Implantation failure: molecular mechanisms and clinical treatment.

Authors:  Hakan Cakmak; Hugh S Taylor
Journal:  Hum Reprod Update       Date:  2010-08-21       Impact factor: 15.610

7.  Polycystic ovary syndrome and maternal obesity affect oocyte size in in vitro fertilization/intracytoplasmic sperm injection cycles.

Authors:  Kerri L Marquard; Sahar M Stephens; Emily S Jungheim; Valerie S Ratts; Randall R Odem; Susan Lanzendorf; Kelle H Moley
Journal:  Fertil Steril       Date:  2010-11-11       Impact factor: 7.329

8.  Association of fat to lean mass ratio with metabolic dysfunction in women with polycystic ovary syndrome.

Authors:  Uche Ezeh; Marita Pall; Ruchi Mathur; Ricardo Azziz
Journal:  Hum Reprod       Date:  2014-05-09       Impact factor: 6.918

9.  Relationship between polycystic ovary syndrome and ancestry in European Americans.

Authors:  Andrew C Bjonnes; Richa Saxena; Corrine K Welt
Journal:  Fertil Steril       Date:  2016-09-22       Impact factor: 7.329

10.  Familial aggregation of circulating C-reactive protein in polycystic ovary syndrome.

Authors:  Arunachalam Sasidevi; Priyathama Vellanki; Allen R Kunselman; Nazia Raja-Khan; Andrea Dunaif; Richard S Legro
Journal:  Hum Reprod       Date:  2012-12-20       Impact factor: 6.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.